Lately it seems as if specialty drugs are everywhere. While it used to be that only a small number of patients were treated using these expensive drugs, manufacturers are increasingly developing specialty products to treat conditions that affect much...
Filed under: Quality, Comparative Effectiveness, Featured, Payment Policy, Costs and Spending, Drugs and Medical Technology, FDA, Sovaldi, Big Pharma, specialty drugs, Biosimiliar, PCSK9 inhibitors